Pavmed Series Z Stock Probability of Future Stock Price Finishing Over 189.43

PAVMZ Stock  USD 0.01  0  32.00%   
PAVmed Series' future price is the expected price of PAVmed Series instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of PAVmed Series Z performance during a given time horizon utilizing its historical volatility. Check out PAVmed Series Backtesting, PAVmed Series Valuation, PAVmed Series Correlation, PAVmed Series Hype Analysis, PAVmed Series Volatility, PAVmed Series History as well as PAVmed Series Performance.
  
Price Earnings To Growth Ratio is likely to rise to 0.01 in 2024, whereas Price To Sales Ratio is likely to drop 11.54 in 2024. Please specify PAVmed Series' target price for which you would like PAVmed Series odds to be computed.

PAVmed Series Target Price Odds to finish over 189.43

The tendency of PAVmed Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 189.43  or more in 90 days
 0.01 90 days 189.43 
close to zero percent
Based on a normal probability distribution, the odds of PAVmed Series to move over $ 189.43  or more in 90 days from now is close to zero percent (This PAVmed Series Z probability density function shows the probability of PAVmed Stock to fall within a particular range of prices over 90 days) . Probability of PAVmed Series Z price to stay between its current price of $ 0.01  and $ 189.43  at the end of the 90-day period is about 88.3 .
Assuming the 90 days horizon PAVmed Series Z has a beta of -2.11 indicating as returns on its benchmark rise, returns on holding PAVmed Series Z are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, PAVmed Series is expected to outperform its benchmark. In addition to that PAVmed Series Z has an alpha of 10.3069, implying that it can generate a 10.31 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   PAVmed Series Price Density   
       Price  

Predictive Modules for PAVmed Series

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as PAVmed Series Z. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.000.0150.52
Details
Intrinsic
Valuation
LowRealHigh
0.000.0150.52
Details

PAVmed Series Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. PAVmed Series is not an exception. The market had few large corrections towards the PAVmed Series' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold PAVmed Series Z, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of PAVmed Series within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
10.31
β
Beta against Dow Jones-2.11
σ
Overall volatility
0.01
Ir
Information ratio 0.19

PAVmed Series Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of PAVmed Series for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for PAVmed Series Z can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
PAVmed Series Z is way too risky over 90 days horizon
PAVmed Series Z has some characteristics of a very speculative penny stock
PAVmed Series Z appears to be risky and price may revert if volatility continues
PAVmed Series Z has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 2.45 M. Net Loss for the year was (64.17 M) with profit before overhead, payroll, taxes, and interest of 0.
PAVmed Series generates negative cash flow from operations
PAVmed Series Z has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters - Financial Times

PAVmed Series Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of PAVmed Stock often depends not only on the future outlook of the current and potential PAVmed Series' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. PAVmed Series' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding7.2 M
Cash And Short Term Investments19.6 M

PAVmed Series Technical Analysis

PAVmed Series' future price can be derived by breaking down and analyzing its technical indicators over time. PAVmed Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of PAVmed Series Z. In general, you should focus on analyzing PAVmed Stock price patterns and their correlations with different microeconomic environments and drivers.

PAVmed Series Predictive Forecast Models

PAVmed Series' time-series forecasting models is one of many PAVmed Series' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary PAVmed Series' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about PAVmed Series Z

Checking the ongoing alerts about PAVmed Series for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for PAVmed Series Z help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
PAVmed Series Z is way too risky over 90 days horizon
PAVmed Series Z has some characteristics of a very speculative penny stock
PAVmed Series Z appears to be risky and price may revert if volatility continues
PAVmed Series Z has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 2.45 M. Net Loss for the year was (64.17 M) with profit before overhead, payroll, taxes, and interest of 0.
PAVmed Series generates negative cash flow from operations
PAVmed Series Z has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters - Financial Times

Additional Tools for PAVmed Stock Analysis

When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.